US Stem Cell Inc (OTCMKTS:USRM) Momentum Favorite Back on the Move

US Stem Cell Inc (OTCMKTS:USRM) Momentum Favorite Back on the Move


US Stem Cell Inc (OTCMKTS:USRM) has been back in rally mode in recent action. This was a major momentum play from early last year – one of the most dramatic stories on the OTC from Jan to March of 2017, rising from deep sub-penny levels to nearly $0.20/share in that time. It was a truly extraordinary run. The catalyst then had to do with a lawsuit that was worked out in a benign fashion. However, this time around, the stock is up a quick 50% in a few days, and breaking out to new multi-month highs, and the move appears to be driven by some more basic ideas related to its core stem cell strategy.

To augment that narrative, the company just announced its participation in this year’s fourth annual Academy of Regenerative Practices’ Conference, which kicked off last week and ran through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida. That conference has come and gone at this point, so the stock’s continued advance raises our eyebrows. We always get interested when a company has made a key presentation and then starts to run on no new headlines. It has the scent of possible “smart money” flows based on key ideas presented at the event. But first, before we get into that thesis, here is a quick overview of the company for those who aren’t familiar with the name.

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.

The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”

Find out when $USRM reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

As noted above, shares of USRM have been back on the move following the company’s appearance at the Academy of Regenerative Practices’ Conference earlier this month.

“It’s always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate,” said Dr. Kristin Comella, USRM’s Chief Science Officer and President of the Academy of Regenerative Practices.  “This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat.  I look forward to another successful conference with my colleagues from around the world.”

The chart shows 40% piled on for shareholders of the company during the trailing month. This is emblematic of the stock. USRM is a stock with a past that has featured a litany of sudden rips to the upside. In addition, the company has registered increased average transaction volume recently, with the past month seeing 49% over the long run average.

Currently trading at a market capitalization of $18.7, USRM has a bankroll ($957K) of cash on the books, which must be weighed relative to about $3.2M in total current liabilities. USRM is pulling in trailing 12-month revenues of $5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 106.4%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $USRM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $USRM, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter